WILMINGTON, Del., April 26, 2019 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.:
- Do you own shares of Aratana Therapeutics, Inc. (NasdaqGM: PETX)?
- Did you purchase any of your shares prior to April 26, 2019?
- Do you think the proposed merger is fair?
- Do you want to discuss your rights?
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Aratana Therapeutics, Inc. (“Aratana” or the “Company”) (NasdaqGM: PETX) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Elanco Animal Health Incorporated and its affiliate (“Elanco”). Under the terms of the agreement, shareholders of Aratana will receive 0.1481 shares of Elanco common stock plus one contingent value right for each share of Aratana common stock they own.
If you own common stock of Aratana and purchased any shares before April 26, 2019, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 300 Delaware Avenue, Suite 1220, Wilmington, Delaware 19801, by telephone at (888) 969-4242, or by e-mail at info@rl-legal.com.
Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT:
Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242
(302) 295-5310
Fax: (302) 654-7530
info@rl-legal.com
http://www.rigrodskylong.com